Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy

被引：3

作者：

Weinstock, Matt ^{[1
]}

Elavalakanar, Pavania ^{[1
]}

Bright, Susan ^{[1
]}

Ambati, Srikanth R. ^{[2
]}

Brouwer-Visser, Jurriaan ^{[2
]}

Pourpe, Stephane ^{[2
]}

Fiaschi, Nathalie ^{[2
]}

Jankovic, Vladimir ^{[2
]}

Thurston, Gavin ^{[2
]}

Deering, Raquel P. ^{[2
]}

Chaudhry, Aafia ^{[2
]}

Joyce, Robin ^{[1
]}

Arnason, Jon ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Hematol Oncol, Boston, MA 02215 USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 03期

关键词：

bispecific antibodies; cellular therapies; clinical trials; non-Hodgkin lymphoma; tumour immunotherapy;

D O I：

10.1111/bjh.18383

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 x CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for >= 2 years following odronextamab. Neither patient experienced Grade >= 3 cytokine release syndrome or Grade >= 3 neurological adverse events during treatment.

引用

页码：366 / 370

页数：5

共 50 条

[1] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
Ernst, Moritz
Oeser, Annika
Besiroglu, Burcu
Caro-Valenzuela, Julia
Aziz, Mohamed Abd El
Monsef, Ina
Borchmann, Peter
Estcourt, Lise J.
Skoetz, Nicole
Goldkuhle, Marius
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
[2] Pyoderma Gangrenosum Secondary to Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
Mager, Layna
Mcfeeters, Jacob
Plaza, Jose A.
Dulmage, Brittany
Kaffenberger, Benjamin H.
WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2025, 37 (01): : 5 - 7
[3] Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study
Tun, Aung M.
Patel, Romil
St-Pierre, Frederique
Ouchveridze, Evguenia
Niu, Alex
Obasi, Jennifer
Rosenthal, Allison C.
Pophali, Priyanka A.
Fenske, Timothy S.
Karmali, Reem
Ahmed, Sairah
Johnston, Patrick B.
BLOOD, 2023, 142
[4] Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma
Yamauchi, Nobuhiko
Maruyama, Dai
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (05) : 662 - 677
[5] Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden
Qu, Changju
Ping, Nana
Kang, Liqing
Liu, Hailing
Qin, Songbin
Wu, Qian
Chen, Xiaochen
Zhou, Meng
Xia, Fan
Ye, Aihua
Kong, Danqing
Li, Caixia
Yu, Lei
Wu, Depei
Jin, Zhengming
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (01) : 32 - 37
[6] Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma
Mulholland, Nicola
Chandra, Julie
Sanderson, Robin
Kuhnl, Andrea
RADIOLOGY, 2023, 307 (05)
[7] Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma
Seyedin, Roxanna
Snider, Julia T.
Rajagopalan, Krithika
Wade, Sally W.
Gergis, Usama
FUTURE ONCOLOGY, 2023, 19 (22) : 1535 - 1547
[8] Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T-cell pathway in patients with diffuse large B-cell lymphoma
Lolli, Ginevra
Argnani, Lisa
Gini, Guido
Casadei, Beatrice
Pellegrini, Cinzia
Tani, Monica
Pavone, Vincenzo
Cimminiello, Michele
Bonifazi, Francesca
Zinzani, Pier Luigi
HEMATOLOGICAL ONCOLOGY, 2023, 41 (05) : 947 - 950
[9] Chimeric Antigen Receptor T-Cell Therapy Treatment Patterns: A Retrospective Cohort Analysis of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in the US
Seyedin, Roxanna
Snider, Julia Thornton
Rajagopalan, Krithika
Wade, Sally W.
Gergis, Usama
BLOOD, 2021, 138
[10] Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Lin, Richard J.
Lobaugh, Stephanie M.
Pennisi, Martina
Chan, Jason T.
Batlevi, Yakup
Ruiz, Josel D.
Elko, Theresa A.
Maloy, Molly A.
Batlevi, Connie Lee
Dahi, Parastoo B.
Giralt, Sergio A.
Mead, Elena
Noy, Ariela
Palomba, Maria Lia
Santomasso, Bianca
Sauter, Craig S.
Scordo, Michael
Shah, Gunjan L.
Korc-Grodzicki, Beatriz
Kim, Soo Jung
Silverberg, Mari Lynne
Brooklyn, Chelsea A.
Devlin, Sean M.
Perales, Miguel-Angel
BLOOD, 2019, 134

← 1 2 3 4 5 →